钙调蛋白磷酸酶B亚基靶向肝癌的研究  

Study on the targeting of the B subunit of calmodulin phosphatase in liver cancer

作　　者：韩丽芳 田树红 HAN Lifang;TIAN Shuhong(Hainan Drug Safety Evaluation Research Center,Hainan Medical College,Hainan Haikou 571199,China)

机构地区：[1]海南医学院海南省药物安全性评价研究中心,海南海口571199

出　　处：《现代肿瘤医学》2023年第18期3342-3346,共5页Journal of Modern Oncology

基　　金：海南省自然科学基金资助项目(编号:818MS068)。

摘　　要：目的:基于小动物活体成像检测技术,探讨重组人钙调蛋白磷酸酶B亚基(rhCNB)的肝癌靶向性。方法:采用肿瘤组织块法建立BALB/c裸小鼠荷人肝癌细胞SMMC-7721原位肝癌模型。原位肝癌模型建立第14天时,按荷瘤动物体重大小随机分为FITC标记的rhCNB(rhCNB-FITC)给药组和FITC对照组,每组12只,各取6只分别用于给药后2 h、24 h剖解取出心脏、肺、肝、胃、双侧肾脏和脾脏用小动物活体成像系统进行荧光检测。另取未接种肿瘤的正常BALB/c裸小鼠随机分为rhCNB-FITC给药组和空白对照组,rhCNB-FITC给药组12只,各取6只分别用于给药后2 h、24 h剖解取相同的脏器进行荧光检测。空白对照组6只,剖解取出相同的脏器进行荧光检测。结果:rhCNB-FITC给予未接种肿瘤的正常动物2 h时,主要分布于动物的肾脏、肝、胃、心和肺,脾脏未见明显分布;24 h时,主要分布于动物的肾脏,肝、胃、心、肺和脾脏未见明显分布。在原位肝癌模型试验中,rhCNB-FITC给药2 h时,主要分布于肝肿瘤、肾脏、肺、胃和心脏等组织器官,脾脏内未检测到明显荧光;FITC给药组只有在肝和胃组织中能检测到荧光,而且荧光强度明显弱于rhCNB-FITC给药组;rhCNB-FITC给药组与FITC对照组肝部(包括正常组织和肝肿瘤组织)的荧光强度比较,P<0.01,具有显著统计学意义。rhCNB-FITC给药24 h时,主要聚集在肝肿瘤、胃、肾脏和肺等组织器官,其中rhCNB在肝肿瘤部位的浓度最高;rhCNB-FITC给药组与FITC对照组肝肿瘤部的荧光强度比较,P<0.05,具有统计学意义。结论:重组人钙调蛋白磷酸酶B亚基具有良好的肝癌靶向性。Objective:To investigate the targeting of recombinant human calmodulin phosphatase B subunit(rhCNB)in liver cancer based on small animal imaging.Methods:The in situ liver cancer model of BALB/c nude mouse with human hepatoma cell SMMC-7721 was established by tumor tissue block method.On the 14th day after the establishment of the in-situ liver cancer model,the animals were randomly divided into FITC-labeled rhCNB(rhCNB-FITC)administration group and FITC control group according to their body weight.There were 12 tumorous mice in each group,and 6 mice were dissected 2 h and 24 h after administration to remove the heart,lung,liver,stomach,bilateral kidney and spleen for fluorescence detection by small animal imaging system.18 normal BALB/c nude mice without tumor inoculation were randomly divided into rhCNB-FITC administration group and blank control group.Among them,6 blank control group were dissected and the same organs were taken out for fluorescence detection.rhCNB-FITC administration group of 12,6 of the same organs were dissected at 2 h and 24 h after administration for fluorescence detection.Results:rhCNB-FITC was mainly distributed in the kidney,liver,stomach,heart and lung of normal animals without tumor inoculation for 2 h,but not in the spleen.At 24 h,it was mainly distributed in the kidney,but not in the liver,stomach,heart,lung and spleen.In the in-situ liver cancer model test,rhCNB-FITC was mainly distributed in liver tumor,kidney,lung,stomach,heart and other tissues and organs after 2 h administration,and no obvious fluorescence was detected in the spleen.Fluorescence was detected only in liver and stomach tissues in FITC administration group,and the fluorescence intensity was significantly lower than rhCNB-FITC administration group.The comparison of fluorescence intensity of liver(including normal tissue and liver tumor tissue)between rhCNB-FITC administration group and FITC control group was statistically significant(P<0.01).At 24 h after administration,rhCNB-FITC mainly concentrated in liver tumor

关 键 词：原位肝癌 钙调蛋白磷酸酶B亚基 肿瘤靶向性 活体成像系统 

分 类 号：R735.7[医药卫生—肿瘤]